Shaheer has been appointed as an Executive Board Member. His knowledge and expertise in advanced medicinal therapies, as well as his global network in academia and industry will serve the natural expansion of Minapharm’s pioneering position in biopharmaceuticals as it continues to place itself for next generation medicines. Shaheer is assigned the responsibility to establish and develop Minapharm’s growth strategy in the field of immuno-oncology and gene and cell-based therapies in collaboration with Minapharm’s subsidiaries in Cairo and Berlin.
Dr. Shaheer Bardissi worked for five years at BioNTech SE, one of Europe’s largest biotech firms and world leader in personalized cancer immunotherapy. He served in the successful development of immunotherapeutic technologies in the cell and gene therapy group lead by Prof. Dr. Ugur Sahin, a world-leading onco-immunologist and BioNTech’s CEO. Shaheer obtained his PhD from Johannes Gutenberg University, Mainz, Germany, with a focus on gene-based immunotherapy. Prior to that, he completed his Master of Science in Molecular Medicine at University College London and his Bachelor of Science in Biomedical Sciences at King’s College London. He is currently a member of the Management Science program in Quantitative Healthcare Business Analytics at Duke University, North Carolina, USA.